Wondfo Biotech joined Novartis, Johnson & Johnson and Consort Medical for a series D round that boosted the in vitro diagnostics developer's total funding to $86m.
UK-based molecular diagnostics technology developer Atlas Genetics completed a $35m series D round yesterday that included medical diagnostics company Wondfo Biotech and pharmaceutical companies Novartis, Johnson & Johnson and Consort Medical.
RMI Partners, LSP, BB Biotech Ventures and Technology Venture Partners also took part in the round. Novartis and Johnson & Johnson invested through respective subsidiaries Novartis Venture Funds and Johnson & Johnson Innovation – JJDC.
Atlas Genetics is working on in vitro diagnostics technology that uses an electrochemical sensor…
